<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576236</url>
  </required_header>
  <id_info>
    <org_study_id>P140928</org_study_id>
    <secondary_id>2015-A00457-42</secondary_id>
    <nct_id>NCT02576236</nct_id>
  </id_info>
  <brief_title>Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection</brief_title>
  <acronym>Hepysé</acronym>
  <official_title>Comparison of the Efficacy and Tolerance of Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance WITH Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection: a Randomised Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The H pylori infection remains a public health problem. The eradication rate with the first&#xD;
      line triple therapy (PPI-amoxicillin-clarithromycin) is insufficient (estimated at 70%) due&#xD;
      to the frequency of resistance to clarithromycin, which reaches 21% in France. Until&#xD;
      now,European and French consensus recomended tofavor sequential therapy (5 days&#xD;
      PPI-amoxicillin and 5 days PPI-clarithromycin-metronidazole) or quadruple bismuth therapy (&#xD;
      10 days PPI-tetracyclin,-metronidazole- bismuth). Studies in countries with low prevalence of&#xD;
      clarithromycin resistance reported eradication rate of 85% with sequential therapy and&#xD;
      reported a low impact of clarithromycin resistance on the effectiveness of this treatment.&#xD;
      However, recent studies suggest a greater impact of clarithromycin resistance. Recent&#xD;
      meta-analysis shows that empiric sequential therapy is less efficacious than concomitant&#xD;
      quadruple therapy. Therefore, recent Maastricht V / Florence meeting October 7-8 2015)&#xD;
      recommended to abandon sequential therapy and to favor 14 days concomitant therapy in first&#xD;
      line in order to reach an eradication rate &gt;90%.&#xD;
&#xD;
      In a multicenter randomized clinical trial (HELICOSTIC 2010-2011 AO ICST 2009), we compared a&#xD;
      triple therapy guided by the results of a PCR test that detects resistance to clarithromycin&#xD;
      and levofloxacin (HelicoDR ®) to empirical triple therapy (PPI-amoxicillin-clarithromycin).&#xD;
      1384 patients and among them 526 infected patients were enrolled in 10 centers. The results&#xD;
      in 415 patients were 73.1% for the empirical treatment versus 85.5% (p &lt;0.001) for the&#xD;
      treatment guided by PCR HelicoDR®. This study also demonstrated the limits of the test&#xD;
      HelicoDR®: onerous, possibility of contamination, little practical contribution of the&#xD;
      determination of resistance to quinolones.&#xD;
&#xD;
      Moreover, it has been shown that triple therapy efficiency could be optimized by increasing&#xD;
      duration up to 14 days and increasing dose of PPI to 40mg b.d;.and eradications rates &gt; 90%&#xD;
      were reported with susceptible to clarithromycin strains.&#xD;
&#xD;
      Adverse events are less common with optimized triple therapy than with concomitant quadruple&#xD;
      therapy.&#xD;
&#xD;
      The main objective is to compare the efficacy of optimized triple therapy guided by the&#xD;
      results of a PCR test (eradication rates 90% hypothesized) with quadruple concomitant therapy&#xD;
      (eradication rate 90% hypothesized).&#xD;
&#xD;
      The secondary objective is to determine side effects of optimized guided triple therapy as&#xD;
      well as the quadruple concomitant therapy in France.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate on the basis of a negative C13 - urea breath test done 6-12 weeks after the end of treatment</measure>
    <time_frame>at 34 month</time_frame>
    <description>Eradication rates will be compared between the patients allocated to standard treatment currently recommended (quadruple concomitant treatment, control group) and patients allocated to triple therapy chosen according to the results of molecular detection of clarithromycin resistance (guided triple therapy,, test group). The breath test is recognized as a sensitive and specific test for infection with H. pylori, particularly in the context of monitoring the efficacy of treatment. It will be carried out blindly to allocated group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety criteria will include all adverse events occurring in the two treatment groups</measure>
    <time_frame>at 34 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>H Pylori Infection Eradication</condition>
  <condition>Antibiotics Therapeutic Strategies</condition>
  <condition>H Pylori Eradication</condition>
  <arm_group>
    <arm_group_label>Triple therapy guided by result of the molecular resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.&#xD;
If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple concomitant therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quadruple concomitant therapy treatment</intervention_name>
    <description>Quadruple concomitant therapy treatment:&#xD;
high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days</description>
    <arm_group_label>Quadruple concomitant therapy</arm_group_label>
    <other_name>therapeutic procedure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Triple therapy guided by the result of the molecular resistance test</intervention_name>
    <description>Triple therapy guided by the result of the molecular resistance test:&#xD;
If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.&#xD;
If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days.</description>
    <arm_group_label>Triple therapy guided by result of the molecular resistance</arm_group_label>
    <other_name>therapeutic procedure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients ≥ 18 years&#xD;
&#xD;
          -  Hospitalized or out-patients referred to one of the participating centers for upper&#xD;
             gastrointestinal endoscopy&#xD;
&#xD;
          -  Who did not received a previous eradication treatment&#xD;
&#xD;
          -  Willing to participate and signed inform consent. Finally only patients with&#xD;
             bacteriologically documented H. pylori infection (PCR) will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having already been treated to eradicate H pylori&#xD;
&#xD;
          -  No affiliation to social insurance&#xD;
&#xD;
          -  Person under legal protection&#xD;
&#xD;
          -  Refusal for signing informed consent&#xD;
&#xD;
          -  Patient included in another trial with medication&#xD;
&#xD;
          -  Patient unable to take oral medication ongoing&#xD;
&#xD;
          -  Patient with severe life-threatening disease in the short term&#xD;
&#xD;
          -  Contraindication to the PPIs, amoxicillin, metronidazole, clarithromycin,&#xD;
             levofloxacin, tetracyclin or bismuth&#xD;
&#xD;
          -  Patient under treatment with antibiotics or PPI without possibility of interruption&#xD;
             for 4 weeks&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Delchier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalila Selmane, CRA</last_name>
      <phone>(0)1 49 81 33 86</phone>
      <phone_ext>+33</phone_ext>
      <email>dalila.selmane@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naïve patient</keyword>
  <keyword>Suspicion of H pylori infection</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Antibiotics therapeutic strategies</keyword>
  <keyword>Urea breath test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

